Eyenovia Inc (NASDAQ:EYEN) shares are trading lower by 39% to $0.41 Wednesday morning after the company announced plans to offer and sell shares of its common stock, or pre-funded warrants, in a best efforts offering. The offering’s size and terms are uncertain and dependent on market conditions. The funds raised will be used for commercializing Mydcombi and clobetasol propionate, completing a pediatric myopia clinical study and for general corporate purposes, including potential debt repayment. Dawson James Securities, Inc. is acting as the sole placement agent for the offering. Read Also: Na…